Bristol Myers Squibb Shares Jump After RYZ101 Phase 3 Interim Win in Rare GEP‑NETs

Bristol Myers Squibb Shares Jump After RYZ101 Phase 3 Interim Win in Rare GEP‑NETs

Tue, October 20, 2026

Shares of Bristol Myers Squibb (NYSE: BMY) surged over 5% in pre-market trading on October 12, 2026 after the company’s subsidiary RayzeBio announced positive topline results from the interim analysis of the Phase 3 ACTION‑1 trial for RYZ101, a radiopharmaceutical therapy targeting gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) that progressed after prior Lutetium‑177 (Lu177) therapy.

The Phase 3 trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression‑free survival (PFS), with safety results aligning with RYZ101’s known profile. Bristol Myers Squibb indicated plans to engage with the U.S. Food and Drug Administration (FDA) on next steps toward regulatory submission, leveraging the drug’s Orphan Drug Designation granted in August 2026. Detailed data from the trial are expected to be shared at an upcoming medical conference. According to Investing.com, this clinical update was the sole market driver amid a flat broader market, underscoring the company‑specific nature of the stock’s move. The stock reached around $62.50 following the announcement. 

KEY DETAILS:

  • ACTION‑1 is a randomized Phase 3 study comparing RYZ101 (225Ac‑DOTATATE) versus investigator’s choice of care—including somatostatin analogs, everolimus or sunitinib—in SSTR‑positive GEP‑NET patients who have progressed after Lu177 therapy. 
  • This interim analysis represents the first randomized, pivotal Phase 3 data for an alpha‑isotope radiopharmaceutical therapy. Bristol Myers highlighted this as a defining milestone for the program and its pipeline. 
  • The Orphan Drug Designation, awarded in August 2026, combined with the interim results, supports ongoing development and positions the company to initiate regulatory discussions. 

RARE DISEASE CONTEXT:

GEP‑NETs are rare tumors, with approximately 18,000 new cases in the U.S. annually and a prevalence under 200,000. Around 80–90% express somatostatin receptor type 2, and most patients progress despite approved Lu177‑based therapies, leaving few treatment options. ACTION‑1 aims to fill this unmet need. 

MARKET REACTION:

Investing.com reported that BMY stock jumped 5.7% in pre‑market trading on October 12, reaching near $62.50, with the broader indices showing minimal movement—highlighting that the rally was strictly linked to the RYZ101 news. 

Why it matters: This trial success marks a potential breakthrough in the nascent field of alpha‑emitting radiopharmaceuticals and enhances Bristol Myers Squibb’s forward‑looking pipeline narrative. The clear PFS signal may accelerate regulatory planning and investor reevaluation of the company’s oncology growth trajectory ahead of its upcoming Q3 earnings report on October 29.

What to watch next: Investors should monitor when the detailed trial data are released, follow updates on FDA engagement or submission timelines, and assess any commentary on commercialization potential, safety profile nuances, or payer reception. These factors will influence whether the share gains are sustained or tempered.